数字化转型是运营模式问题，却常伪装成技术采购，因此软件上线后数据通常不会改变。 医疗服务提供商面临特定困境—— downside risk 已接受于38,000 条生命，但缺乏按 episode 定价所需的成本数据。在定价前，单次 episode 成本会因无人能归因的原因持续变动，技术支出占收入比例的讨论将始终停留在意见层面。
数字化转型是运营模式问题，却常伪装成技术采购，因此软件上线后数据通常不会改变。 医疗服务提供商面临特定困境—— downside risk 已接受于38,000 条生命，但缺乏按 episode 定价所需的成本数据。在定价前，单次 episode 成本会因无人能归因的原因持续变动，技术支出占收入比例的讨论将始终停留在意见层面。
这些项目一再令人失望的原因是排序错误，而非技术错误。平台大多能用。失败之处在于系统会编码流程，而被编码的流程通常是现有流程——它通过逐步积累形成，包含各种例外、变通，以及只有三人知道第六步为何存在的隐性知识。忠实数字化后，得到的是同一个东西的昂贵版本，只是更难改变了。
第二个失败是商业论证用技术单位撰写，收益却在运营单位。许可证、集成、迁移和培训精确且落在第一年。收益——更少手动操作、更短周期、更少返工——不精确且落在第二、三年（前提是流程确实重新设计）。若未重新设计，成本真实，收益只剩幻灯片。
真正战略问题值得单独讨论：技术改变的是你能卖什么，还是仅改变运行成本。二者答案与预算不同。分销商若能向客户提供实时可用性，即为商业变化；若仅自动化拣货，即为成本变化。两者都值得做；混为一谈则产生无法验证的商业论证。
Digital & Technology Strategy（目录编号 t8）按此顺序处理问题——今日流程实际成本、成本中属于决策而非工具的部分、论证属于商业还是运营——然后才进入供应商选择。若答案是简单实施且回报清晰，则直接说明，实施伙伴即为下一步。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 平台已入围短名单，但目标流程尚未绘制
✓ 商业论证基于许可证节省，而非周期时间或人力
✓ 此前系统成功上线，但运营数据未变
通常会让情况更糟的做法。 先选系统再重新设计流程，将运营模式问题转化为定制预算。
It is for you if you run or finance a healthcare provider and a platform has been shortlisted and the target process has not been drawn. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Digital & Technology Strategy, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
工作不同。咨询公司用于决定应改变什么及论证；集成商用于让选定平台运行。找集成商回答战略问题，会得到未审视流程的极佳实施。找咨询公司做实施，会得到更慢、更贵的集成商。
中型市场中，咨询部分通常为£80k–£300k，耗时八至十六周。其后的实施通常是该费用的五至二十倍，因此咨询阶段值得比其预算份额更多的 scrutiny——它决定了之后所有规模。
取一笔交易，统计手动操作次数及各次之间的等待时间。若大部分流逝时间是等待决策或批准，即为流程与治理问题，新系统会保留它。若大部分是重新录入、核对或查询，即为真正的工具问题，技术会移动数据。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית